At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 30 enrolled
Drug / intervention
Dexmedetomidine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pharmacodynamic Interactions Between Remifentanil and Dexmedetomidine (PIRAD)
In Brief
A Phase 4 clinical trial evaluating Dexmedetomidine and Remifentanil for Anesthesia. Completed, enrolled 30 participants across 1 site.
Detailed Summary
The objective is to map the pharmacokinetic / pharmacodynamic interaction between dexmedetomidine and remifentanil by observing changes in anesthetic depth. These changes will be related to drug concentrations using pharmacokinetic/pharmacodynamic (PKPD) modeling.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnesthesia
CountriesNetherlands
Collaborators--
Timeline
Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedMay 2017
Enrollment StartJun 2017
Primary CompletionFeb 2018
TodayJul 2026
First PostedMay 8, 2017
Enrollment StartJun 28, 2017
Primary CompletionFeb 23, 2018
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 9.2 years ago
Interventions
Dexmedetomidinedrug
Single drug administration
Remifentanildrug
Single drug administration